Cutia Therapeutics (2487.HK)
HKD 6.95
(0.14%)
HKD 6.95
(0.14%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 137.62 Million | 11.36 Million | 2.03 Million |
| Cost of Revenue | 66.61 Million | 3.42 Million | 428 Thousand |
| Gross Profit | 71 Million | 7.93 Million | 1.61 Million |
| Operating Expenses | 71 Million | 310.89 Million | 178.41 Million |
| Selling, General and Administrative Expenses | 255.16 Million | 35.8 Million | 16.55 Million |
| Research and Development Expenses | 215.71 Million | 180.75 Million | 110.55 Million |
| Other Expenses | - | -326.67 Million | -120.26 Million |
| Cost and Expenses | 677.27 Million | 314.31 Million | 178.83 Million |
| Operating Income | -539.65 Million | -538.28 Million | -313.98 Million |
| Interest Expense | 4.47 Million | 1.72 Million | 559 Thousand |
| Income Tax Expense | - | - | - |
| Earnings before Tax | -1.96 Billion | -555.83 Million | -319.58 Million |
| Net Income | -1.96 Billion | -555.83 Million | -319.58 Million |
| Earnings Per Share Basic | -9.60 | -6.94 | -3.99 |
| Earnings Per Share Diluted | -9.60 | -6.94 | -3.99 |
| Weighted Average Shares Outstanding | 204.61 Million | 80.04 Million | 80.04 Million |
| Weighted Average Shares Outstanding (Diluted) | 204.61 Million | 80.04 Million | 80.04 Million |
| Gross Margin | 0.52 | 0.70 | 0.79 |
| EBIT Margin | -13.93 | -45.69 | -149.26 |
| Profit Margin | -14.27 | -48.90 | -156.81 |
| EBITDA | -1.91 Billion | -535.18 Million | -309.22 Million |
| Earnings Before Tax Margin | -3.92 | -47.36 | -154.06 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 47.78 Million | 47.78 Million | 51.64 Million | 137.62 Million | 51.64 Million | 17.17 Million |
| Cost of Revenue | 22.62 Million | 22.62 Million | 26.76 Million | 66.61 Million | 26.76 Million | 6.54 Million |
| Gross Profit | 25.16 Million | 25.16 Million | 24.87 Million | 71 Million | 24.87 Million | 10.63 Million |
| Operating Expenses | 135.04 Million | 135.04 Million | 187.27 Million | 597.98 Million | 190.47 Million | 836.37 Million |
| Selling, General and Administrative Expenses | 85.54 Million | 85.54 Million | 124.49 Million | - | 124.49 Million | 72.98 Million |
| Research and Development Expenses | 49.5 Million | 49.5 Million | 62.78 Million | - | 62.78 Million | 45.06 Million |
| Other Expenses | - | - | - | -1.47 Billion | - | - |
| Cost and Expenses | 157.66 Million | 157.66 Million | 214.04 Million | 664.59 Million | 217.24 Million | 842.91 Million |
| Operating Income | -109.87 Million | -109.87 Million | -162.4 Million | -539.65 Million | -162.4 Million | -107.42 Million |
| Interest Expense | - | - | - | 4.47 Million | - | - |
| Income Tax Expense | - | - | - | -1.42 Billion | - | - |
| Earnings before Tax | -100.46 Million | -100.46 Million | -161.7 Million | -1.96 Billion | -161.7 Million | -820.16 Million |
| Net Income | -100.46 Million | -100.46 Million | -161.7 Million | -1.96 Billion | -161.7 Million | -820.16 Million |
| Earnings Per Share Basic | -0.33 | -0.33 | -0.53 | - | -0.53 | -7.92 |
| Earnings Per Share Diluted | -0.33 | -0.33 | -0.53 | - | -0.53 | -7.92 |
| Weighted Average Shares Outstanding | 304.73 Million | 304.73 Million | 305.67 Million | 204.61 Million | 305.67 Million | 103.55 Million |
| Weighted Average Shares Outstanding (Diluted) | 304.73 Million | 304.73 Million | 305.67 Million | 204.61 Million | 305.67 Million | 103.55 Million |
| Gross Margin | 0.53 | 0.53 | 0.48 | 0.52 | 0.48 | 0.62 |
| EBIT Margin | -2.15 | -2.15 | -3.00 | - | -3.00 | -5.81 |
| Profit Margin | -2.10 | -2.10 | -3.13 | -14.27 | -3.13 | -47.76 |
| EBITDA | -102.6 Million | -102.6 Million | -154.7 Million | - | -154.7 Million | -99.69 Million |
| Earnings Before Tax Margin | -2.30 | -2.30 | -3.14 | -3.92 | -3.14 | -6.26 |
0543
ELO
DATS
SESG
TWR
NAH